Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Friday.

A number of other research firms also recently issued reports on ACRS. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Friday, December 15th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $39.20.

Aclaris Therapeutics (NASDAQ ACRS) opened at $22.09 on Friday. Aclaris Therapeutics has a 52 week low of $21.32 and a 52 week high of $33.25. The company has a market cap of $682.06 and a PE ratio of -10.23.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.23. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $2.00 million. equities research analysts expect that Aclaris Therapeutics will post -2.59 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ACRS. Citigroup Inc. boosted its holdings in Aclaris Therapeutics by 171.8% in the 2nd quarter. Citigroup Inc. now owns 4,313 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 2,726 shares during the period. Legal & General Group Plc boosted its holdings in Aclaris Therapeutics by 98.3% in the 2nd quarter. Legal & General Group Plc now owns 5,254 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 2,605 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at about $142,000. Voya Investment Management LLC bought a new stake in Aclaris Therapeutics in the 2nd quarter valued at about $247,000. Finally, Trexquant Investment LP bought a new stake in Aclaris Therapeutics in the 3rd quarter valued at about $247,000. 92.35% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/02/02/aclaris-therapeutics-acrs-stock-rating-lowered-by-bidaskclub.html.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.